

不可逆激动剂 α -CAM 与阿片受点内巯基结合的反应¹李建国、李灵源、叶莱英、金荫昌²、虞鑫红³、刘懋勤³(中国医学科学院基础医学研究所药理室, 北京 100005; ³上海医科大学药学院, 上海 200032)*Acta Pharmacologica Sinica* 1989 Mar; 10(2): 97-100Irreversible action of the opioid agonist α -CAM and its reaction with SH groups at opioid receptor binding sites¹LI Jian-Guo, LI Ling-Yuan, YE Cai-Ying, JIN Yin-Chang, YU Xin-Hong², LIU Mao-Qin² (Department of Pharmacology, Institute of Basic Medical Sciences, Chinese Academy of Sciences, Beijing 100005; ²College of Pharmacy, Shanghai Medical University, Shanghai 200032)

Abstract 7 α -bis(β -chloroethyl)aminomethyl-6,14-endoethenotetrahydrooripavine (α -CAM) was found to bind to opioid receptors irreversibly and react directly with sulfhydryl (SH) groups in P₂ preparations of rat brain. The P₂ preparations were pretreated as follows: protection of the SH groups at the opioid receptor binding sites by morphine or etorphine, and inactivation of the SH groups outside the binding sites by N-ethylmaleimide (NEM), followed by removal of the morphine or etorphine by washing. α -CAM was still able to bind the pretreated P₂ preparations in an irreversible manner. The results indicate that the formation of covalent bonds between α -CAM and the SH groups of opioid receptor binding sites is possibly one of the biochemical mechanisms of the irreversible action of α -CAM.

Key words endorphin receptors; analgesics; 7 α -bis(β -chloroethyl)aminomethyl-6,14-endoethenotetrahydrooripavine (α -CAM); sulfhydryl compounds; binding sites; alkylating agents

提要 7 α -二(β -氯乙基)胺甲基-6, 14-乙烯撑基四氢奥利文(α -CAM)能与阿片受点不可逆结合, 并直接作用于大鼠脑 P₂ 膜的巯基。将 P₂ 膜用吗啡或依托啡预处理以保护阿片受点内巯基不被后加的 NEM 烷化, 然后冲洗暴露受点内巯基, α -CAM 仍能与 P₂ 膜形成不可逆结合, 提示 α -CAM 与阿片受点内巯基结合是其不可逆作用的生化机理之一。

关键词 内啡肽受体; 镇痛药; 7 α -二(β -氯乙基)胺甲基-6,14-乙烯撑基四氢奥利文(α -CAM); 巯基化合物; 结合位点; 烷化剂


自第一个阿片受体烷化剂合成⁽¹⁾以来, 已有不少关于阿片生物碱类和脑啡肽类不可逆配体的报道, 有的已用于阿片受体纯化和亚型的研究⁽²⁾。我们报道合成的新化合物 α -CAM (7 α -二(β -氯乙基)胺甲基-6,14-乙烯撑基四氢奥利文 (7 α -bis(β -chloroethyl)aminomethyl-6, 14-endoethenotetrahydrooripavine)⁽³⁾ 具有超长效镇痛作用, 是阿片受体的不可逆激动剂⁽⁴⁾。本文初步研究了 α -CAM 不可逆作用的生化机理。

1988年2月1日收稿 1988年8月28日接受

¹ 本文为国家自然科学基金资助课题 No 3860260

² 课题负责人

¹ Project supported by National Natural Science Foundation of China, No 3860260



7 α -Bis(β -chloroethyl) aminomethyl-6,14-endoethenotetrahydrooripavine (α -CAM)

Materials and methods

α -CAM, 依托啡(Eto), [^3H]Eto(1221 GBq/mmol)和[^3H]纳洛酮([^3H]Nal, 999 GBq/mmol)由上海医科大学药学院合成和标记; 吗啡(Mor)由东北第六制药厂生产, 经重结晶及氧化铝柱层析纯化; *N*-乙基顺丁烯二酰亚胺(*N*-ethylmaleimide, NEM)由中国科学院生物化学研究所合成; 5,5'-二硫双(2-硝基苯甲酸)(5,5'-dithiobis(2-nitrobenzoic acid), DTNB)由防化研究院合成。

放射受点结合试验 Wistar大鼠, 110只, 体重 $184 \pm \text{SD } 19 \text{ g}$, 雌雄不拘。大鼠脑(去小脑)的 P_2 膜制备和放射受点结合试验方法见文献(5)。不可逆结合试验采用冲洗法(5,6), 将药物与大鼠脑 P_2 膜一起温孵后, 用Tris-HCl 50 mmol/L缓冲液(pH 7.5)冲洗5次, 每次加缓冲液混悬后放置5 min, 然后离心, $16000 \times g$, 4°C , 20 min, 弃去上清液。

巯基含量测定 大鼠脑 P_2 膜制备的巯基含量采用DTNB法(7)测定。

Results

α -CAM与大鼠脑阿片受点的不可逆结合 α -CAM(20 $\mu\text{mol/L}$)与大鼠脑 P_2 膜一起 30°C 温孵30 min后, 洗涤5次, 用[^3H]Eto进行放射受点饱和结合试验。结果经计算机Scatchard分析, 表明阿片受点的高、低亲和力结合均未恢复(Fig 1)。

NEM对阿片受点结合活性的影响 巯基烷化剂NEM不仅能抑制大鼠脑阿片受点与激动剂[^3H]Eto 1.1 nmol/L的结合, 也能抑制




Fig 1. Irreversible binding of 7 α -bis(β -chloroethyl) aminomethyl-6,14-endoethenotetrahydrooripavine (α -CAM) with opiate receptors. P_2 membrane preparations of rat brain (without cerebellum) were preincubated with α -CAM (20 $\mu\text{mol/L}$) for 30 min at 30°C and washed 5 times, then the [^3H]etorphine (Eto) binding activity of opiate receptors was determined. Scatchard plot with a computer shows that neither high nor low affinity binding activity of opiate receptors was recovered.




Fig 2. Inhibition of [^3H]etorphine-opiate receptor binding and [^3H]naloxone-opiate receptor binding by *N*-ethylmaleimide (NEM). Rat brain P_2 membrane preparations (1 mg protein) were incubated with [^3H]etorphine (Eto) 1.1 nmol/L (or [^3H]naloxone(Nal) 0.8 nmol/L) in the presence (non-specific binding, cpm_n) or absence (total binding, cpm_t) of Eto 5 $\mu\text{mol/L}$ (Nal 4 $\mu\text{mol/L}$) or NEM of different concentrations (binding in the presence of inhibitor, cpm_i). The % of inhibition of [^3H]Eto (or [^3H]Nal) binding by NEM were given by $(\text{cpm}_t - \text{cpm}_i) / (\text{cpm}_t - \text{cpm}_n)$.

阿片受点与拮抗剂[^3H]Nal 0.8 nmol/L的结合(Fig 2), 表明巯基对阿片受点的结合活性是必需的。

α -CAM 对大鼠脑 P_2 膜巯基的作用 用 DTNB 法测定的半胱氨酸标准曲线来衡量大鼠脑 P_2 膜中巯基的含量, 结果表明含 5 mg 蛋白质的 P_2 膜巯基的含量为 $22.4 \pm 1.9 \mu\text{mol/L}$ ($n=6$).

α -CAM 和 NEM 对大鼠脑 P_2 膜巯基含量的影响均有剂量依赖性. α -CAM 的作用比 NEM 弱, 但两药浓度增大时, 均可使 P_2 膜巯基的含量减少到接近于零 (Fig 3).




Fig 3. The dose-effect relationship of α -CAM and NEM on sulfhydryl group concentrations in rat brain P_2 membrane preparations (containing 5 mg protein). $n=3$, $\bar{x} \pm \text{SD}$.

α -CAM 与阿片受体不可逆结合部位的检定 用大剂量 Mor (12 mmol/L) 预先与大鼠脑 P_2 膜一起 30°C 温孵 20 min, 再加入 NEM 20 mmol/L 继续温孵 20 min, 然后用 Tris-HCl 缓冲液冲洗 5 次, 分别测定洗涤前后 P_2 膜与 $[^3\text{H}]\text{Eto}$ (1.1 nmol/L) 的特异结合量. 结果表明 Mor 保护的 P_2 膜经冲洗后其结合 $[^3\text{H}]\text{Eto}$ 的活性明显恢复 (Fig 4).

用上述受到 Mor 保护的 P_2 膜与 α -CAM (10 $\mu\text{mol/L}$) 一起 30°C 温孵 20 min, 冲洗 5 次后再测定洗涤前后 P_2 膜对 $[^3\text{H}]\text{Eto}$ 的结合活性. 结果表明反复冲洗也不能解除 α -CAM 与阿片受点的结合 (Fig 5).

用大剂量 Eto (2.5 mmol/L) 代替 Mor, 也得到相同结果.




Fig 4. The protection of morphine (Mor) from inactivation of $[^3\text{H}]\text{Eto}$ -opiate receptors binding by NEM. $n=3$, $\bar{x} \pm \text{SD}$. A) (Mor + NEM): Rat brain P_2 membrane preparations were preincubated with Mor (12 mmol/L) for 20 min at 30°C and then incubated with NEM (20 mmol/L) for 20 min at 30°C , and washed 5 times, finally the ability of specific binding ($\text{cpm}_t - \text{cpm}_n$) of opiate receptors with $[^3\text{H}]\text{Eto}$ (1.1 nmol/L) was determined. B) (NEM): Tris-HCl buffer (50 mmol/L, pH 7.5) plus NEM. C) (Control): The Tris-HCl buffer only. *P > 0.05, ***P < 0.01 vs C or A or B before washes.




Fig 5. Irreversible binding of α -CAM with opiate receptors protected by Mor from inactivation by NEM. $n=3$, $\bar{x} \pm \text{SD}$. A) (Mor + NEM): See legend of Fig 4. B) (Mor + NEM + α -CAM): Rat brain P_2 membrane preparations were pretreated with Mor and NEM, and then washed. This P_2 membrane preparations in which Mor was removed by 5 washes and NEM bound with sulfhydryl groups out of opiate receptor binding sites existed were incubated with α -CAM (10 $\mu\text{mol/L}$) for 20 min at 30°C and washed 5 times again, finally the $[^3\text{H}]\text{Eto}$ (1.1 nmol/L) binding activity of opiate receptors was determined. C) (Control): See legend of Fig 4. *P > 0.05 vs C or B before washes, ***P < 0.01 vs A.

Discussion

能与受点(即受体分子的特异结合部位)或与受点附近的基团形成共价键结合的配体称为不可逆配体。 α -CAM 是带有氯乙胺氮芥基团的阿片受体不可逆配体,其氯乙胺基团在一定条件下可氯解形成吖丙啶鎓(aziridinium)离子,后者化学性质活泼,能够与受体上多种亲核基团如巯基、羟基、氨基等共价结合。Portoghese 等⁽⁸⁾曾推测带有富马酰基团的 β -funaltrexamine(β -FNA)的不可逆生化机理可能与阿片受体的巯基有关,但未见实验证据。本文用实验方法证明了 α -CAM 与阿片受点内巯基结合。我们还研究了 α -CAM 类似物,阿片受点不可逆部分激动剂 A- α -CAM 的不可逆生化机理,也取得相同的结果(待发表资料)。

阿片受体上的巯基与受点的结合活性有关已得到公认,本文的结果也支持这一结论。

药理实验已证明 α -CAM 是阿片受体不可逆激动剂^(3,4),并且当 α -CAM 剂量增大时,可使 P_2 膜巯基的含量减少到接近于零,这都提示 α -CAM 使 P_2 膜巯基含量减少的主要原因是其与巯基共价结合。NEM 是一种对阿片受体无特异性的巯基烷化剂,因此,它对 P_2 膜巯基的作用比 α -CAM 强。

为了检定 α -CAM 是与阿片受点内的巯基还是受点外(或邻近)的巯基结合,我们先用大剂量的可逆性阿片受体激动剂 Mor 或 Eto 将受点内巯基保护起来,再用 NEM 烷化受点外的巯基,然后冲洗掉 Mor 或 Eto,使受点内巯基重新暴露。由于 α -CAM 仍能与这种预处理的 P_2 膜不可逆结合,这提示 α -CAM 可能与阿片受点内的巯基形成共价结合。

目前对阿片受体的其他亲核基团如羟基、氨基等的研究报道尚少,因此 α -CAM 的不可

逆生化机理除与阿片受点内的巯基形成共价结合外,是否与其他活性基团也有关,尚待进一步研究。

References

- 1 Portoghese PS, Larson DL, Jiang JB, Takemori AE, Caruso TP. 6β -[N,N-Bis(2-chloroethyl)amino]-17-(cyclopropylmethyl)-4,5 α -epoxy-3,14-dihydroxymorphinan (Chloranal-trexamine), a potent opioid receptor alkylating agent with ultralong narcotic antagonist activity. *J Med Chem* 1978; 21: 598
- 2 Li MX, Jin YC. Irreversible ligands of opioid receptors and their application in the study of these receptors. *Acta Pharm Sin* 1985; 20: 940
- 3 Yu XH, Liu MQ, Li LY, Li JG, Wang L, Suo CL. Synthesis and biological activity of some thebaine and oripavine derivatives with flexible electrophilic chains. *Ibid* 1987; 22: 501
- 4 李建国,李灵源,金荫昌.一种新的阿片受点不可逆激动剂—7 α -二(β -氯乙基)胺甲基-6,14-乙烯撑基四氢奥利文. *中国医学科学院学报* 1987; 9: 449
- 5 Li LY, Ye CY, Zhang ZR, Wang L, Jin YC. Four long acting analgesic hydrazone derivatives of opiates which bind more firmly with opiate receptors. *Acta Pharmacol Sin* 1985; 6: 152
- 6 Ward SJ, Fries DS, Larson DL, Portoghese PS, Takemori AE. Opioid receptor binding characteristics of the non-equilibrium μ antagonist, β -funaltrexamine (β -FNA). *Eur J Pharmacol* 1985; 107: 323
- 7 Sedlak J, Lindsay RH. Estimation of total, protein-bound, and nonprotein sulfhydryl groups in tissue with Ellman's reagent. *Anal Biochem* 1968; 25: 192
- 8 Portoghese PS, Larson DL, Sayre LM, Fries DS, Takemori AE. A novel opioid receptor site directed alkylating agent with irreversible narcotic antagonistic and reversible agonistic activities. *J Med Chem* 1980; 23: 233